Table 3 Site of infections and isolated pathogens in the 128 targeted antimicrobial therapies underwent ECPA program

Site of infections^a

Pneumonia

50 (38.2%)

Bloodstream infection

34 (26.0%)

Complicated intra-abdominal infection

29 (22.1%)

Complicated urinary tract infection

9 (6.9%)

Bone and joint infection

4 (3.1%)

Necrotizing soft tissue infection

2 (1.5%)

Meningitis

2 (1.5%)

Catheter-related bloodstream infection

1 (0.7%)

Isolated pathogens^b

Gram-positive (9)

 Staphylococcus aureus

7 (5.1%)

 Enterococcus faecium

2 (1.4%)

Gram-negative (115)

 Pseudomonas aeruginosa

31 (22.6%)

 Escherichia coli

24 (17.5%)

 Klebsiella pneumoniae

22 (16.1%)

 Proteus mirabilis

7 (5.1%)

 Enterobacter cloacae complex

7 (5.1%)

 Klebsiella aerogenes

6 (4.3%)

 Serratia marcescens

4 (2.9%)

 Klebsiella oxytoca

2 (1.4%)

 Klebsiella variicola

2 (1.4%)

 Morganella morganii

2 (1.4%)

 Acinetobacter baumannii

2 (1.4%)

 Proteus vulgaris

1 (0.7%)

 Citrobacter koseri

1 (0.7%)

 Hafnia alvei

1 (0.7%)

 Pantoea spp

1 (0.7%)

 Acinetobacter pittii

1 (0.7%)

 Stenotrophomonas maltophilia

1 (0.7%)

Anaerobes (1)

 Bacteroides faecis

1 (0.7%)

Atypical (4)

 Legionella pneumophila

4 (2.9%)

Fungi (8)

 Candida albicans

5 (3.7%)

 Candida glabrata

1 (0.7%)

 Aspergillus fumigatus

1 (0.7%)

 Aspergillus terreus

1 (0.7%)

Virus

 CMV reactivation

1 (0.7%)